科学家测试治疗湿疹的新方法
![Graphic Depiction of Experimental Atopic Dermatitis and Treatment Protocol. Atopic dermatitis (AD)-like phenotype was induced in 8-week-old C57BL/6 female mice by topical application of MC903 (calcipotriol), an analog of vitamin D3. On day 1, an initial bolus dose of 6 nmoles of MC903 was applied topically to the right ear (3 nmoles on each side of the ear). On day 3, dosing once a day (Q.D.) with 2 nmoles of MC903 (1 nmole on each side of the right ear) was begun and continued for 3 weeks. On day 20, a 9-day twice-daily (B.I.D.) topical treatment with 66 nmoles NTCI (cSN50.1 peptide, 33 nmoles on each side of the right ear), or an equal volume of NTCI vehicle (10 µl saline on each side of the right ear) was initiated. Mice were weighed and ear thickness was measured every 2–4 days. Ear samples were collected on day 29 for gene expression and Immunohistochemistry (IHC) analyses. Mice in the Mock Control group were only subjected to the measurements of body weight and the ear thickness. Credit: Scientific Reports (2022). DOI: 10.1038/s41598-022-23042-x 科学家测试治疗湿疹的新方法](https://scx1.b-cdn.net/csz/news/800a/2023/scientists-test-new-wa.jpg)
范德比尔特大学医学中心的研究人员开发了一种新的研究药物,可以在特应性皮炎-湿疹的临床前模型中阻断炎症信号。
湿疹是最常见的复发性炎症性皮肤病,全世界约有10%至20%的儿童和5%的成年人患有湿疹,其中非洲裔美国人发病率最高。症状和体征包括强烈的瘙痒,皮疹和可感染的渗出和结痂病变,可影响睡眠和日常活动。
严重湿疹的治疗方法包括免疫抑制药物为了控制炎症,单克隆抗体它能中和被称为细胞因子或其受体的炎症蛋白,以及对抗感染的抗生素。然而,这些治疗方法不能治愈或完全控制湿疹,其中一些药物可能会引起严重的副作用。
相比之下,VUMC研究人员开发的肽药物沉默细胞因子表达基因,抑制皮肤浸润炎症细胞,痊愈了皮肤损伤,至少在动物模型中没有明显的毒性。
“我们通过证明我们可以控制至少15个负责产生皮肤炎症主要介质的基因,从而揭示了湿疹的机制,”首席研究员Jacek Hawiger博士说,他是VUMC的杰出医学教授和Louise B. McGavock教授。
哈威格和他的同事在11月7日的杂志上报告了他们的发现科学报告.这种外用药物直接应用于发炎的皮肤,目前正在多中心临床试验中对患有糖尿病的患者进行测试湿疹.
更多信息:刘燕等,实验性特应性皮炎炎症的基因组控制,科学报告(2022)。DOI: 10.1038 / s41598 - 022 - 23042 - x